Comparison · NCT03696342-ff677dd6
PRO-157 vs Zymar: Presence of Bacterial Eradication Compared to Baseline Culture Results
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PRO-157 vs Zymar: Presence of Bacterial Eradication Compared to Baseline Culture Results. Trial comparisons, record NCT03696342-ff677dd6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03696342-ff677dd6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.864 | 0.667 | 0.953 | wilson | |
| Risk in group 2 | 0.957 | 0.79 | 0.992 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0929 | -0.293 | 0.0958 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.903 | 0.749 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | 0.288 | 0.0276 | 3 | log | |
| Number needed to treat, for one fewer participant with the outcome on PRO-157 than on Zymar | 10.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PRO-157 | Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.~Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days. | 19 | 22 | OG000 |
| Group 2 | Zymar | Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.~Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days. | 22 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Presence of Bacterial Eradication Compared to Baseline Culture Results
- Description
The conjunctival secretion sample will be taken prior to the instillation of any medication, the result of the basal crop will be compared against the results of the final crop and the absence of bacterial species that were present in the culture of the baseline visit is considered bacterial eradication.
- Time frame
- will be evaluated at the end of the treatment (day 8, final visit)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.
- NCT number
- NCT03696342
- Phases
- PHASE3
- Conditions
- Conjunctivitis, Bacterial
- Interventions
- Pazufloxacin, Zymar
- Lead sponsor
- Laboratorios Sophia S.A de C.V.
- Results first posted
- 2021-08-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03696342?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03696342-ff677dd6